ArticleEye (London, England)2026
Olink proteomics profiling platform reveals inflammatory protein biomarkers in vitreous with different degrees of proliferative vitreoretinopathy.
Article in Eye (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aims to investigate the role of inflammation in proliferative vitreoretinopathy (PVR) by analysing inflammation-related proteins in vitreous samples and identifying potential biomarkers for PVR severity.
methodsVitreous samples were collected from patients with different stages of PVR (control group, n = 15; PVR A/B, n = 15; PVR C/D, n = 14). Using an Onlink proteomics panel, the levels of 92 inflammation-related proteins were measured. Differential expression analysis was conducted to identify proteins significantly altered between the PVR and control groups. AlphaFold3 modelling was employed to predict common binding peptide segments among differentially expressed proteins. Additionally, the impact of PVR vitreous on inflammatory cytokine production in retinal pigment epithelium (RPE) cells was assessed to explore the functional consequences of the observed protein changes.
resultsThe proteomic analysis revealed differential expression of 63 inflammation-related proteins between the PVR and control groups. Among these, MCP-1 exhibited significant variations across PVR stages and demonstrated high diagnostic value for PVR presence (AUC = 0.949) and severity (PVR C/D, AUC = 0.719). AlphaFold3 modelling identified a common binding peptide segment, INAPVTCCYN, shared by MCP-1, CCL3, CCL4 and CXCL9, suggesting their potential collaborative role in PVR progression. Furthermore, vitreous samples from PVR patients significantly stimulated inflammatory cytokine production in RPE cells, indicating a functional link between vitreous inflammation and retinal pathology.
conclusionsPVR is associated with elevated levels of vitreous inflammation and MCP-1 is a promising biomarker for predicting and diagnosing PVR severity. The identification of a common binding peptide segment and the stimulation of cytokine production in RPE provide mechanistic insights into PVR progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.